Business
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulm
About this update from Roivant Sciences Ltd.
[{"type":"image","alt":"Pulmovant, Inc.","displaySize":"","headline":null,"caption":"Pulmovant, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZxCXGBa_9wg7zAAgfIM2Mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5c95ec62cb928b13aafcaaf1396a38dd","width":300,"height":108}},"lazy":false},{"type":"text","content":"Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects","length":128,"tagName":"p"},{"type":"text","content":"Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)","length":159,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a Roivant (Nasdaq: ROIV) company, today announced the publication of Phase 1 pharmacokinetics (PK) in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension (PH). The peer-reviewed manuscript titled, “Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men,” was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.","length":1129,"tagName":"p"},{"type":"text","content":"“We are very pleased to announce the publication of Phase 1 PK data in Clinical Pharmacokinetics, which support once daily administration of inhaled mosliciguat and its continued development for the treatment of patients with pulmonary hypertension,” said Ubaldo ...